<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00207831</url>
  </required_header>
  <id_info>
    <org_study_id>CPP276</org_study_id>
    <nct_id>NCT00207831</nct_id>
  </id_info>
  <brief_title>Trial Testing Ftorafur (UFT) Associated With Neoadjuvant Radiotherapy Versus Radiotherapy Alone in Rectal Adenocarcinoma</brief_title>
  <acronym>UFT RT Phase 3</acronym>
  <official_title>Trial UFT/RT Randomized Multicenter Phase III Randomized Trial Testing Ftorafur (UFT) Associated With Neoadjuvant Radiotherapy Versus Radiotherapy Alone in Rectal Adenocarcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ICO Paul Papin</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>ICO Paul Papin</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy, such as 5-fluorouracil, work in different ways to stop
      the growth of tumor cells, either by killing the cells or by stopping them from dividing and
      also as a radiosensibilisant. Radiation therapy uses high-energy x-rays to kill tumor cells.
      5-fluorouracil may make tumor cells more sensitive to radiation therapy. Oral 5-fluorouracil
      is more convenient for ambulatory patients. Giving UFT (Tegafur and Uracil) with radiation
      therapy before surgery may shrink the tumor so it can be removed.

      PURPOSE: This phase III trial is studying how well giving UFT with radiation therapy works in
      treating patients who are undergoing surgery for operable rectal cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Adenocarcinoma of the rectum

      Stage II/stage III rectal cancer (if T4 only anal extension eligible)

      Drug: UFT

      Procedure: chemotherapy

      Procedure: conventional surgery

      Procedure: neoadjuvant therapy

      Procedure: radiation therapy

      Procedure: radiosensitization

      Procedure: surgery
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Terminated after interim analysis
  </why_stopped>
  <start_date>July 2004</start_date>
  <completion_date type="Actual">February 2008</completion_date>
  <primary_completion_date type="Actual">June 2007</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Compare the rate of pathologic complete response of the primary tumor in patients with operable rectal cancer receiving preoperative chemoradiotherapy versus patients receiving radiotherapy alone</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Compare endoscopic ultrasonographic response in patients with operable rectal cancer receiving preoperative chemoradiotherapy versus patients receiving radiotherapy alone.</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compare quality of life (Quality of Life Questionnaire Core 30 Items [QLQ-C 30])</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compare the rate of sphincter conservation alone.</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compare the safety of the chemoradiotherapy regimen to radiotherapy alone</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compare the rate of resectability with negative resection margins in patients treated with this two regimen.</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compare recurrence free survival and disease free survival</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compare overall survival</measure>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">219</enrollment>
  <condition>Rectal Cancer</condition>
  <condition>Stage II/III</condition>
  <condition>T3 or T4 (Only Anal Extension) Rectal Cancer</condition>
  <condition>N0-2</condition>
  <condition>M0</condition>
  <arm_group>
    <arm_group_label>Tegafur uracile + radiotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>radiotherapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tegafur and Uracil</intervention_name>
    <arm_group_label>Tegafur uracile + radiotherapy</arm_group_label>
    <arm_group_label>radiotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Histologically confirmed invasive adenocarcinoma of the rectum , M0, lower side &lt; 10
             cm from anal verge

          -  T3 or T4 disease (T4 exclusive anal extension )

        PATIENT CHARACTERISTICS:

        Performance status

          -  ECOG 0-2 OR

          -  Zubrod 0-2

        Life expectancy

          -  Not specified

        Hematopoietic

          -  Absolute neutrophil count &gt; 1,500/mm^3

          -  Platelet count ≥ 100,000/mm^3

        Hepatic

          -  Bilirubin &lt; x2 UNL

        Renal

          -  Creatinine &lt; 150 µMol/L

        Gastrointestinal

          -  No history of inflammatory bowel disease

          -  No history of difficulty or inability to take or absorb oral medications

        Neurologic

          -  Not specified

        Other

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Fertile patients must use effective contraception

          -  No other malignancy within the past 5 years except curatively treated basal cell skin
             cancer or carcinoma in situ of the cervix

          -  No history of psychiatric conditions or diminished mental capacity that would preclude
             study compliance or giving informed consent

        PRIOR CONCURRENT THERAPY:

        Chemotherapy

          -  No prior chemotherapy

        Radiotherapy

          -  No prior radiotherapy to the pelvis

        Other

          -  No other concurrent investigational drugs

          -  No other concurrent anticancer treatment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Patrice Cellier, MD</last_name>
    <role>Study Chair</role>
    <affiliation>ICO Paul Papin</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Rémy Barraya, MD</last_name>
    <role>Study Chair</role>
    <affiliation>ICO Paul Papin</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Christian Chevelle, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Centre des Hautes Energie, Toulouse</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Gérard Lorimier, MD</last_name>
    <role>Study Chair</role>
    <affiliation>ICO Paul Papin</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Véronique Verrièle, MD</last_name>
    <role>Study Chair</role>
    <affiliation>ICO Paul Papin</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Michèle Boisdron, Pct, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>ICO Paul Papin</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Loïc Campion, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Centre René Gauducheau, Nantes</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Clinique Sainte Catherine</name>
      <address>
        <city>Avignon</city>
        <zip>84000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Avicenne</name>
      <address>
        <city>Bobigny</city>
        <zip>93</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut de Cancérologie et d'Hématologie</name>
      <address>
        <city>Brest</city>
        <zip>29609</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier</name>
      <address>
        <city>Brive La Gaillarde</city>
        <zip>19312</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre d'Oncologie-radiothérapie d'Eure et Loir</name>
      <address>
        <city>Chartres</city>
        <zip>28006</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Jean Perrin</name>
      <address>
        <city>Clermont Ferrand</city>
        <zip>63011</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Médical République</name>
      <address>
        <city>Clermont-ferrand</city>
        <zip>63023</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique du Mail</name>
      <address>
        <city>Grenoble</city>
        <zip>38100</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Départemental</name>
      <address>
        <city>La Roche Sur Yon</city>
        <zip>85025</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Guillaume le Conquérant</name>
      <address>
        <city>Le Havre</city>
        <zip>76600</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Oscar Lambret</name>
      <address>
        <city>Lille</city>
        <zip>59020</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier</name>
      <address>
        <city>Lorient</city>
        <zip>56322</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre léon Bérard</name>
      <address>
        <city>LYON Cedex 08</city>
        <zip>69373</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Gray</name>
      <address>
        <city>Maubeuge</city>
        <zip>59600</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique du Pont de Chaume</name>
      <address>
        <city>Montauban</city>
        <zip>82017</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Polyclinique St Roch</name>
      <address>
        <city>Montpellier</city>
        <zip>34967</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique Valdegour</name>
      <address>
        <city>Nimes</city>
        <zip>30900</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier</name>
      <address>
        <city>Niort</city>
        <zip>79021</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire</name>
      <address>
        <city>Poitiers</city>
        <zip>86021</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de Cornouaille</name>
      <address>
        <city>Quimper</city>
        <zip>29000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Eugène Marquis</name>
      <address>
        <city>Rennes</city>
        <zip>35042</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier</name>
      <address>
        <city>Rodez</city>
        <zip>12027</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Frédéric Joliot</name>
      <address>
        <city>Rouen</city>
        <zip>76000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique Armoricaine de Radiologie</name>
      <address>
        <city>Saint Brieuc</city>
        <zip>22015</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre de Radiothérapie</name>
      <address>
        <city>Strasbourg</city>
        <zip>67000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre des Hautes Energies</name>
      <address>
        <city>Toulouse</city>
        <zip>31400</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique Fleming</name>
      <address>
        <city>Tours</city>
        <zip>37000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>July 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 13, 2005</study_first_submitted>
  <study_first_submitted_qc>September 13, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 21, 2005</study_first_posted>
  <last_update_submitted>July 20, 2010</last_update_submitted>
  <last_update_submitted_qc>July 20, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 21, 2010</last_update_posted>
  <responsible_party>
    <name_title>Centre Paul¨Papin</name_title>
    <organization>Gamelin Pr</organization>
  </responsible_party>
  <keyword>rectal cancer</keyword>
  <keyword>neoadjuvant therapy</keyword>
  <keyword>UFT</keyword>
  <keyword>radiochemotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
    <mesh_term>Rectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tegafur</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

